TABLE 2 from CALGB 80802 (Alliance): Impact of Sorafenib with and without Doxorubicin on Hepatitis C Infection in Patients with Advanced Hepatocellular Carcinoma

<p>Cox proportional hazards model results for PFS and OS. Each row reflects a model with that variable; models across all patients are stratified on treatment arm. Baseline HCV only includes those with pretreatment HCV titer data available (<i>n</i> = 43), and first sample HCV includes baseline HCV titer data for those with it available and cycle 2 data for those missing baseline (<i>n</i> = 53)</p>

Duke Scholars

Author Andrew Benjamin Nixon Medicine, Medical Oncology